Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
10.71
-0.14 (-1.29%)
Jul 31, 2025, 3:14 PM - Market open
Grifols Revenue
Grifols had revenue of 1.79B EUR in the quarter ending March 31, 2025, with 9.85% growth. This brings the company's revenue in the last twelve months to 7.37B, up 10.76% year-over-year. In the year 2024, Grifols had annual revenue of 7.21B with 9.41% growth.
Revenue (ttm)
7.37B EUR
Revenue Growth
+10.76%
P/S Ratio
1.08
Revenue / Employee
310,590 EUR
Employees
23,737
Market Cap
9.43B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.21B | 620.41M | 9.41% |
| Dec 31, 2023 | 6.59B | 528.01M | 8.71% |
| Jan 1, 2023 | 6.06B | 1.13B | 22.92% |
| Dec 31, 2021 | 4.93B | -406.92M | -7.62% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 57.37B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
GRFS News
- 7 weeks ago - XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewsWire
- 2 months ago - Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting - Business Wire
- 2 months ago - US court finds enough evidence to proceed with Grifols lawsuit against Gotham City - Reuters
- 2 months ago - Grifols: If This Works Out, It Has Massive Upside - Seeking Alpha
- 2 months ago - Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - Grifols says on course to meet 2025 outlook as net profit triples - Reuters
- 4 months ago - IBL International collaborates with Grifols on advanced biomarker panels - Business Wire
- 4 months ago - Brookfield resumes Grifols takeover talks, El Confidencial reports - Reuters